Previously, in a single-institutional study, TMEM173 and FADD were reported as potential biomarkers at proteomic-level analysis (53); however, the current study is the first report of an antiangiogenic treatment biomarker at the OS level, validated by two recurrent GBM clinical trials. Here, FADD is linked to glioblastoma.